AR078045A1 - Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer - Google Patents
Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancerInfo
- Publication number
- AR078045A1 AR078045A1 ARP100101776A ARP100101776A AR078045A1 AR 078045 A1 AR078045 A1 AR 078045A1 AR P100101776 A ARP100101776 A AR P100101776A AR P100101776 A ARP100101776 A AR P100101776A AR 078045 A1 AR078045 A1 AR 078045A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- methyl
- alkoxy
- cr9r10
- phenyl
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- -1 -NR11R12 Chemical group 0.000 abstract 1
- 125000001963 4 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- YQBBGVHNQDCFSW-UHFFFAOYSA-N ethyl 3-[[2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl]methyl]benzoate Chemical compound CCCCCNC1=NC(N)=NC(C)=C1CC1=CC=CC(C(=O)OCC)=C1 YQBBGVHNQDCFSW-UHFFFAOYSA-N 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000005113 hydroxyalkoxy group Chemical group 0.000 abstract 1
- RWMMYTWSPPVCOJ-UHFFFAOYSA-N methyl 4-[[2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl]methyl]-3-methoxybenzoate Chemical compound CCCCCNC1=NC(N)=NC(C)=C1CC1=CC=C(C(=O)OC)C=C1OC RWMMYTWSPPVCOJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000004894 pentylamino group Chemical group C(CCCC)N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Composiciones farmacéuticas que los contienen y su uso en l tratamiento de enfermedades, por ejemplo, cáncer. Reivindicacion 1: Un compuesto de la Formula (1), o una sal farmacéuticamente aceptable del mismo caracterizado porque: X representa -CH2-, -NR8-, -O- o -S(O)n-; R1 representa alquiloC1-6, alcoxiC2-6, alcoxiC1-6alquiloC1-6, hidroxialquiloC1-6, hidroxialcoxiC1-6 o hidroxialcoxiC1-6alquiloC1-6; R2 representa hidrogeno, alquiloC1-6 o fenilo donde dicho fenilo se sustituye opcionalmente por 1, 2 o 3 sustituyentes seleccionados de R6; R3 representa alquiloC1-6, alcoxiC1-6 o -S-alquiloC1-6; R4 representa hidrogeno, halogeno, alquiloC1-6 o alcoxiC1-6; L1 representa un enlace directo, -(CR9R10)m-, -CH=CH-(CR9R10)q-, -C:::C-(CR9R10)q-, -O-(CR9R10)q-, -C(O)-O-(CR9R10)q- o -O-(CH2)qNR8-(CH2)q-; R5 representa metilo, hidroxi, -NR11R12, cicloalquiloC3-6, fenilo o un anillo monocíclico, o heterocíclico de 4, 5, 6 o 7 miembros que comprende 1, 2 o 3 heteroátomos seleccionados independientemente de O, N o S donde dichos fenilo y anillos heterocíclicos se sustituyen opcionalmente por 1, 2 o 3 sustituyentes seleccionados de R7; R6 representa alquiloC1-6 , fluoroalquiloC1-6, alcoxiC1-6, hidroxi, halogeno, ciano, -S(O)n-alquiloC1-6 o -CH2-C(O)-O-alquiloC1-6; R7 representa alquiloC1-6, alcoxiC1-6, aIcoxiC1-6alquiloC1-6, hidroxi, hidroxialquiloC1-6, o -(CH2)q-NR11R12; R8 representa hidrogeno o alquiloC1-6; R9 y R10, idéntica o diferentemente en cada caso, representa hidrogeno o metilo; R11 y R12 independientemente representan hidrogeno, alquiloC1-4 o alcoxiC1-4alquiloC2-4; m representa 1, 2, 3, 4, 5 o 6; n representa 0, 1 o 2; y q representa, 0, 1, 2, 3, 4, 5 o 6; con la condicion de que el compuesto de la Formula (1) no sea: etil éster del ácido [3-(2-amino-4-metil-6-pentilamino-pirimidin-5-ilmetil)]-benzoico; 4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)-3-metoxibenzoato de metilo; o 4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-iI)metil)-3-fluorobenzoato de metilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18023809P | 2009-05-21 | 2009-05-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078045A1 true AR078045A1 (es) | 2011-10-12 |
Family
ID=42315702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101776A AR078045A1 (es) | 2009-05-21 | 2010-05-21 | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20120122867A1 (es) |
| EP (1) | EP2432768B1 (es) |
| JP (1) | JP5913093B2 (es) |
| KR (1) | KR20120030436A (es) |
| CN (1) | CN102482233A (es) |
| AR (1) | AR078045A1 (es) |
| AU (1) | AU2010250923A1 (es) |
| BR (1) | BRPI1010937A2 (es) |
| CA (1) | CA2760766A1 (es) |
| CL (1) | CL2011002942A1 (es) |
| CO (1) | CO6470845A2 (es) |
| CR (1) | CR20110610A (es) |
| CU (1) | CU20110212A7 (es) |
| DO (1) | DOP2011000361A (es) |
| EA (1) | EA201101650A1 (es) |
| EC (1) | ECSP11011470A (es) |
| IL (1) | IL216283A0 (es) |
| MX (1) | MX2011012337A (es) |
| SG (1) | SG175796A1 (es) |
| TW (1) | TW201100083A (es) |
| UY (1) | UY32648A (es) |
| WO (1) | WO2010133885A1 (es) |
| ZA (1) | ZA201109384B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2644286T3 (es) | 2009-10-22 | 2017-11-28 | Gilead Sciences, Inc. | Derivados de purina o deazapurina útiles para el tratamiento de (entre otros) infecciones víricas |
| WO2012066335A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
| WO2012067268A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Cyclic amide compounds and their use in the treatment of disease |
| WO2012066336A1 (en) * | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Benzylamine compounds as toll -like receptor 7 agonists |
| WO2012067269A1 (en) * | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
| JP5978225B2 (ja) | 2010-12-16 | 2016-08-24 | 大日本住友製薬株式会社 | 治療に有用なイミダゾ［４，５−ｃ］キノリン−１−イル誘導体 |
| DK2651943T3 (en) | 2010-12-17 | 2017-06-06 | Sumitomo Dainippon Pharma Co Ltd | purine derivatives |
| SG191830A1 (en) | 2011-01-10 | 2013-08-30 | Cleveland Biolabs Inc | Use of toll-like receptor agonist for treating cancer |
| SMT201800527T1 (it) | 2011-04-08 | 2018-11-09 | Janssen Sciences Ireland Uc | Derivati della pirimidina per il trattamento di infezioni virali |
| UA116083C2 (uk) | 2011-11-09 | 2018-02-12 | ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі | Похідні пурину для лікування вірусних інфекцій |
| FR2985256B1 (fr) * | 2011-12-30 | 2016-03-04 | Pitty Marc Henry | Derives piperazinyles pour le traitement de cancers |
| JP6283320B2 (ja) * | 2012-02-08 | 2018-02-21 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染の治療のためのピペリジノ−ピリミジン誘導体 |
| EP2850067B1 (en) * | 2012-05-18 | 2017-08-16 | Sumitomo Dainippon Pharma Co., Ltd. | Carboxylic acid compounds |
| PT2872515T (pt) | 2012-07-13 | 2016-07-27 | Janssen Sciences Ireland Uc | Purinas macrocíclicas para o tratamento de infeções virais |
| ES2701098T7 (es) * | 2012-10-05 | 2021-02-03 | Janssen Sciences Ireland Unlimited Co | Derivados de acilaminopirimidina para el tratamiento de infecciones víricas y otras enfermedades |
| SG11201502622VA (en) | 2012-10-10 | 2015-05-28 | Janssen Sciences Ireland Uc | PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES |
| NZ706226A (en) | 2012-11-16 | 2019-09-27 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| WO2014128189A1 (en) * | 2013-02-21 | 2014-08-28 | Janssen R&D Ireland | 2-aminopyrimidine derivatives for the treatment of viral infections |
| JP6336036B2 (ja) | 2013-03-29 | 2018-06-06 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染治療のための大環状デアザプリノン |
| WO2014187932A1 (en) * | 2013-05-24 | 2014-11-27 | Janssen R&D Ireland | Pyridone derivatives for the treatment of viral infections and further diseases |
| DK3030563T3 (da) | 2013-06-27 | 2017-11-20 | Janssen Sciences Ireland Uc | Pyrrolo-[3,2-d]-pyrimidin-derivater til behandling af virale infektioner og andre sygdomme |
| JP6401788B2 (ja) | 2013-07-30 | 2018-10-10 | ヤンセン・サイエンシズ・アイルランド・ユーシー | ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体 |
| JP6940916B2 (ja) | 2014-07-30 | 2021-09-29 | ゲノム プロテクション，インコーポレイテッド | フラジェリン組成物および使用 |
| MA40774A (fr) * | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| WO2016109002A2 (en) | 2014-10-16 | 2016-07-07 | Cleveland Biolabs, Inc. | Methods and compositions for the treatment of radiation-related disorders |
| PT3360864T (pt) * | 2015-10-07 | 2021-06-02 | Sumitomo Dainippon Pharma Co Ltd | Composto de pirimidina |
| CN109476675B (zh) | 2016-07-01 | 2022-12-09 | 爱尔兰詹森科学公司 | 用于治疗病毒性感染的二氢吡喃并嘧啶衍生物 |
| AU2017335205B2 (en) | 2016-09-29 | 2021-11-04 | Janssen Sciences Ireland Unlimited Company | Pyrimidine prodrugs for the treatment of viral infections and further diseases |
| US10786502B2 (en) | 2016-12-05 | 2020-09-29 | Apros Therapeutics, Inc. | Substituted pyrimidines containing acidic groups as TLR7 modulators |
| MX387236B (es) * | 2016-12-05 | 2025-03-18 | Apros Therapeutics Inc | Compuestos de pirimidina que contienen grupos ácidos |
| JP7169968B2 (ja) | 2017-03-29 | 2022-11-11 | 住友ファーマ株式会社 | ワクチンアジュバント製剤 |
| CN116115765A (zh) | 2017-12-21 | 2023-05-16 | 住友制药株式会社 | 包含tlr7激动剂的组合药物 |
| MX2020008746A (es) * | 2018-02-28 | 2020-09-28 | Hoffmann La Roche | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. |
| TW201945003A (zh) | 2018-03-01 | 2019-12-01 | 愛爾蘭商健生科學愛爾蘭無限公司 | ２，４－二胺基喹唑啉衍生物及其醫學用途 |
| WO2019236496A1 (en) | 2018-06-04 | 2019-12-12 | Apros Therapeutics, Inc. | Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7 |
| CA3107409A1 (en) | 2018-07-23 | 2020-01-30 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
| BR112021015577A8 (pt) | 2019-02-08 | 2021-10-05 | Research & Business Found Sungkyunkwan Univ | Complexo-colesterol agonista do receptor toll-like 7/8, composição de nanopartícula, composição adjuvante, composição de vacina, composição para regular uma função imunológica, composição farmacêutica e uso do complexo |
| WO2021177679A1 (ko) | 2020-03-02 | 2021-09-10 | 성균관대학교산학협력단 | 병원균 외벽 성분 기반 생병원체 모방 나노 입자 및 그 제조 방법 |
| EP4194008A4 (en) | 2020-08-04 | 2025-01-08 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| WO2022031057A1 (ko) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 기능성 약물의 결합체 및 그 용도 |
| JP7690222B2 (ja) | 2020-08-04 | 2025-06-10 | プロジェニア インコーポレイテッド | 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1375162A (es) | 1970-10-22 | 1974-11-27 | ||
| GB1546937A (en) | 1976-07-29 | 1979-05-31 | Beecham Group Ltd | 2,4-diaminopyrimidine derivatives |
| ZA848968B (en) | 1983-11-18 | 1986-06-25 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
| DE3603577A1 (de) | 1986-02-06 | 1987-08-13 | Joachim K Prof Dr Seydel | Neue substituierte 2,4-diamino-5-benzylpyrimidine, deren herstellung und deren verwendung als arzneimittel mit antibakterieller wirksamkeit |
| JPH08165292A (ja) | 1993-10-07 | 1996-06-25 | Techno Res Kk | アデニン誘導体、その製造法及び用途 |
| US6110923A (en) | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
| CA2201773A1 (en) | 1994-10-05 | 1996-04-18 | John Montana | Purine and guanine compounds as inhibitors of pnp |
| CA2230808C (en) | 1996-07-03 | 2006-08-15 | Japan Energy Corporation | A novel purine derivative |
| WO1999028321A1 (fr) | 1997-11-28 | 1999-06-10 | Sumitomo Pharmaceuticals Company, Limited | Nouveaux composes heterocycliques |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| JP4189048B2 (ja) | 1997-12-26 | 2008-12-03 | 大日本住友製薬株式会社 | 複素環化合物 |
| WO1999050249A2 (en) | 1998-04-01 | 1999-10-07 | Du Pont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
| JP4497340B2 (ja) * | 1998-08-27 | 2010-07-07 | 大日本住友製薬株式会社 | ピリミジン誘導体 |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| WO2001007027A2 (en) | 1999-07-22 | 2001-02-01 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives for the treatment of viral diseases |
| US20020128264A1 (en) | 2000-07-07 | 2002-09-12 | Taylor Eve M. | Methods for treatment of conditions affected by activity of multidrug transporters |
| ATE404561T1 (de) | 2001-04-17 | 2008-08-15 | Dainippon Sumitomo Pharma Co | Neue adeninderivate |
| WO2003043588A1 (fr) * | 2001-11-22 | 2003-05-30 | Japan Science And Technology Agency | Modele animal non humain ne reagissant pas a un compose synthetique d'immunopotentialisation |
| AU2003246102A1 (en) | 2002-06-27 | 2004-01-19 | Genox Research, Inc. | Method of examining allergic disease and drug for treating the same |
| US7754728B2 (en) | 2002-09-27 | 2010-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound and use thereof |
| MXPA05013922A (es) | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| US7442698B2 (en) | 2003-07-24 | 2008-10-28 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| EP1667694B1 (en) | 2003-09-05 | 2010-04-28 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| CN1845745B (zh) * | 2003-09-05 | 2011-11-02 | 安那迪斯药品股份有限公司 | Tlr7配体及其前药在制备用于治疗丙型肝炎病毒感染的药物中的用途 |
| JPWO2005092892A1 (ja) | 2004-03-26 | 2008-02-14 | 大日本住友製薬株式会社 | ８−オキソアデニン化合物 |
| TWI414525B (zh) | 2004-03-26 | 2013-11-11 | Dainippon Sumitomo Pharma Co | ９-取代-８-氧基腺嘌呤化合物 |
| KR100700676B1 (ko) | 2005-06-24 | 2007-03-28 | (주) 비엔씨바이오팜 | 6―（4―치환된―아닐리노）피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물 |
| NZ566722A (en) | 2005-09-15 | 2010-11-26 | Orchid Res Lab Ltd | Novel pyrimidine carboxamides |
| WO2007034817A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
| WO2008001070A1 (en) | 2006-06-30 | 2008-01-03 | Astrazeneca Ab | Pyrimidine derivatives useful in the treatment of cancer |
| CL2007002231A1 (es) | 2006-08-02 | 2008-04-11 | Basf Ag | Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico. |
| WO2008083465A1 (en) | 2007-01-08 | 2008-07-17 | University Health Network | Pyrimidine derivatives as anticancer agents |
| US8044056B2 (en) | 2007-03-20 | 2011-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | Adenine compound |
| AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
| ES2452965T3 (es) | 2007-09-05 | 2014-04-03 | Rigel Pharmaceuticals, Inc. | Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina |
| PE20091236A1 (es) * | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
-
2010
- 2010-05-20 CA CA2760766A patent/CA2760766A1/en not_active Abandoned
- 2010-05-20 US US13/321,407 patent/US20120122867A1/en not_active Abandoned
- 2010-05-20 WO PCT/GB2010/050825 patent/WO2010133885A1/en active Application Filing
- 2010-05-20 CN CN2010800338249A patent/CN102482233A/zh active Pending
- 2010-05-20 KR KR1020117030498A patent/KR20120030436A/ko not_active Withdrawn
- 2010-05-20 JP JP2012511356A patent/JP5913093B2/ja active Active
- 2010-05-20 MX MX2011012337A patent/MX2011012337A/es not_active Application Discontinuation
- 2010-05-20 AU AU2010250923A patent/AU2010250923A1/en not_active Abandoned
- 2010-05-20 EP EP10721195.5A patent/EP2432768B1/en active Active
- 2010-05-20 UY UY0001032648A patent/UY32648A/es not_active Application Discontinuation
- 2010-05-20 BR BRPI1010937A patent/BRPI1010937A2/pt not_active IP Right Cessation
- 2010-05-20 EA EA201101650A patent/EA201101650A1/ru unknown
- 2010-05-20 SG SG2011078433A patent/SG175796A1/en unknown
- 2010-05-21 TW TW099116416A patent/TW201100083A/zh unknown
- 2010-05-21 AR ARP100101776A patent/AR078045A1/es unknown
-
2011
- 2011-11-10 IL IL216283A patent/IL216283A0/en unknown
- 2011-11-21 DO DO2011000361A patent/DOP2011000361A/es unknown
- 2011-11-21 EC EC2011011470A patent/ECSP11011470A/es unknown
- 2011-11-21 CR CR20110610A patent/CR20110610A/es unknown
- 2011-11-21 CL CL2011002942A patent/CL2011002942A1/es unknown
- 2011-11-21 CU CU20110212A patent/CU20110212A7/es unknown
- 2011-11-30 CO CO11165091A patent/CO6470845A2/es not_active Application Discontinuation
- 2011-12-20 ZA ZA2011/09384A patent/ZA201109384B/en unknown
-
2014
- 2014-08-26 US US14/469,515 patent/US9533978B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120030436A (ko) | 2012-03-28 |
| CO6470845A2 (es) | 2012-06-29 |
| CL2011002942A1 (es) | 2012-04-13 |
| CN102482233A (zh) | 2012-05-30 |
| MX2011012337A (es) | 2011-12-08 |
| UY32648A (es) | 2010-12-31 |
| US20120122867A1 (en) | 2012-05-17 |
| JP2012527443A (ja) | 2012-11-08 |
| ZA201109384B (en) | 2012-09-26 |
| CA2760766A1 (en) | 2010-11-25 |
| US9533978B2 (en) | 2017-01-03 |
| CU20110212A7 (es) | 2012-03-15 |
| BRPI1010937A2 (pt) | 2019-09-24 |
| EA201101650A1 (ru) | 2012-07-30 |
| CR20110610A (es) | 2012-01-09 |
| JP5913093B2 (ja) | 2016-04-27 |
| EP2432768B1 (en) | 2017-07-05 |
| ECSP11011470A (es) | 2011-12-30 |
| SG175796A1 (en) | 2011-12-29 |
| TW201100083A (en) | 2011-01-01 |
| DOP2011000361A (es) | 2011-12-15 |
| WO2010133885A1 (en) | 2010-11-25 |
| IL216283A0 (en) | 2012-01-31 |
| US20150080396A1 (en) | 2015-03-19 |
| EP2432768A1 (en) | 2012-03-28 |
| AU2010250923A1 (en) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| CY1118739T1 (el) | Ενωσεις αμφι(φθoρoαλκυλ)-1,4-βενζoδιαζεπινoνης ως αναστολεις toy notch | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| AR077977A1 (es) | Compuestos y composiciones como inhibidores de cinasa de proteina | |
| PE20151601A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| UY30498A1 (es) | Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones | |
| CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
| CO6470846A2 (es) | Derivados aminobut´ricos sustituidos como inhibidores de neprilisina | |
| ATE517882T1 (de) | Chinolinderivate | |
| PE20141598A1 (es) | Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR050952A1 (es) | Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1. | |
| AR054129A1 (es) | Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7 | |
| AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| AR055744A1 (es) | Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |